Abstract
Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and colleagues show here that peritumoral delivery of low doses of this immunomodulatory drug can trigger a systemic antitumor immune response while preventing the toxicity against other organs.
Original language | English |
---|---|
Pages (from-to) | 5261-5263 |
Number of pages | 3 |
Journal | Clinical Cancer Research |
Volume | 19 |
Issue number | 19 |
DOIs | |
Publication status | Published - 1 Oct 2013 |
Externally published | Yes |